Cambridge Heart Ups Marketing In Anticipation Of MTWA National Coverage
This article was originally published in The Gray Sheet
Executive Summary
Anticipating a positive national coverage decision from CMS by March 21, Cambridge Heart is aggressively targeting private payors with its HeartWave II Microvolt T-Wave Alternans (MTWA) test
You may also be interested in...
People In Brief
Boston Sci. names quality chief: William E. Young signs on as VP-quality assurance & reliability for Boston Scientific's cardiac rhythm management group. The firm recently acquired the heart rhythm business, which has been dogged with several high-profile recalls, including the latest product withdrawal, announced June 23 (1"The Gray Sheet" July 3, 2006, p. 14). Young will be responsible for product performance reporting for the firm's pacemakers and implantable cardioverter defibrillators. Previously, Young served as VP-quality assurance & regulatory affairs for Smiths Medical in London. Before that, he handled quality management for Baxter Healthcare's medication delivery division...
People In Brief
Boston Sci. names quality chief: William E. Young signs on as VP-quality assurance & reliability for Boston Scientific's cardiac rhythm management group. The firm recently acquired the heart rhythm business, which has been dogged with several high-profile recalls, including the latest product withdrawal, announced June 23 (1"The Gray Sheet" July 3, 2006, p. 14). Young will be responsible for product performance reporting for the firm's pacemakers and implantable cardioverter defibrillators. Previously, Young served as VP-quality assurance & regulatory affairs for Smiths Medical in London. Before that, he handled quality management for Baxter Healthcare's medication delivery division...
CMS Proposes National Coverage For Microvolt T-Wave Alternan Testing
Cambridge Heart (HeartWave II) appears to have prevailed in its quest to obtain national coverage for Microvolt T-Wave Alternan testing to evaluate patients at risk of sudden cardiac death, despite opposition from professional societies and the three major ICD firms